Mono- or di-fluorinated analogues of flavone-8-acetic acid: synthesis and in vitro biological activity. 2005

Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
Department of Pharmacology and Anaesthesiology, University of Padova, Largo Meneghetti 2, 35131 Padova, Italy. maria.carrara@unipd.it

BACKGROUND Previously, the antitumour activity of some flavone-8-acetic acid (FAA) derivatives substituted with an acid function in position 2 of the benzene ring was evaluated. The most active compound resulted the one bearing a fluorine atom in position 7 of the flavone nucleus. In this paper, we evaluated new mono- or di-fluorinated FAA derivatives. METHODS The cytotoxicity towards two human ovarian adenocarcinoma cell lines, the capability to stimulate human mononuclear cells and murine macrophages' lytic properties were evaluated by MTT. Moreover, the potentiation of lipopolysaccharide (LPS) activity was studied by ELISA analysis of TNF-alpha release. RESULTS The analogues showed a direct cytotoxicity comparable to that of 5,6-dimethyl-xanthen-9-one-4-acetic acid (DMXAA), at present in clinical trials. None of the tested compounds was able to stimulate human mononuclear cells' lytic properties after either 4- or 24-h treatment, while after 4-h treatment, the derivative 5a was more able to stimulate murine macrophages with respect to DMXAA. Moreover, a significant increase of 5c and 5d activation was obtained with LPS association, reflected by TNF-alpha production as well. CONCLUSIONS Like FAA, the new fluorinated derivatives 5a, 5c and 5d showed remarkable activity in murine cells, but this was not confirmed in human models.

UI MeSH Term Description Entries
D008297 Male Males
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005260 Female Females
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006845 Hydrocarbons, Fluorinated Inert liquid or gaseous halocarbon compounds in which FLUORINE replaces some or all HYDROGEN atoms. Fluorinated Hydrocarbons
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
April 1996, Anti-cancer drug design,
Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
June 1994, Drug design and discovery,
Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
July 1992, International journal of peptide and protein research,
Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
May 2008, Journal of medicinal chemistry,
Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
August 2016, Anticancer research,
Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
June 1989, Journal of the National Cancer Institute,
Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
August 2003, Journal of medicinal chemistry,
Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
June 1992, Biochemical pharmacology,
Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
February 1988, Lancet (London, England),
Maria Carrara, and Antonella Zampiron, and Mariagnese Barbera, and Anna Caputo, and Alessandra Bisi, and Silvia Gobbi, and Federica Belluti, and Lorna Piazzi, and Angela Rampa, and Piero Valenti
September 1989, European journal of cancer & clinical oncology,
Copied contents to your clipboard!